Trial · NCT00300742
Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals
NCT00300742, Phase 2, Completed, University of Virginia; results first posted 2017-05-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals. Trials, record NCT00300742. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00300742
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals
- NCT number
- NCT00300742
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- University of Virginia
- Conditions
- Alcohol Dependence, Binge Eating
- Interventions
- Topiramate
- First posted
- 2006-03-09
- Last updated
- 2017-07-12
- Results first posted
- 2017-05-11
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Compliance With Study Requirements: Attendance at Treatment Sessions | up to 12 weeks | |
| Primary | Mean Drinks Per Day at Baseline vs. Visit 12 | up to 24 weeks | Mean drinks per day at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary |
| Primary | Mean Percent Days Abstinent Per Week at Baseline vs. Visit 12 | up to 24 weeks | Mean percent days abstinent per week at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary |
| Primary | Mean Binge Eating Episodes Per Week at Baseline vs. Visit 12 | up to 24 weeks | Mean binge eating episodes per week at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary |
| Primary | Compliance With Study Requirements: Topiramate Level | up to 12 weeks | Number of subjects who escalated to the maximum dose of 300 mg of topiramate/day |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Compliance With Study Requirements: Attendance at Treatment Sessions | up to 12 weeks | participants | NUMBER | |
| PRIMARY | Mean Drinks Per Day at Baseline vs. Visit 12 | up to 24 weeks | Per protocol | Drinks/day | MEAN |
| PRIMARY | Mean Percent Days Abstinent Per Week at Baseline vs. Visit 12 | up to 24 weeks | Per protocol | Mean percent days abstinent per week | MEAN |
| PRIMARY | Mean Binge Eating Episodes Per Week at Baseline vs. Visit 12 | up to 24 weeks | Per protocol | Binge eating episodes/week | MEAN |
| PRIMARY | Compliance With Study Requirements: Topiramate Level | up to 12 weeks | This is the number of participants who reached the dose of 300 mg of topiramate | participants | NUMBER |
Source ClinicalTrials.gov
Results by group9
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Compliance With Study Requirements: Attendance at Treatment Sessions | Topiramate/BBCET | Number of subjects completed through Visit 4 | 5 | participants | |
| Compliance With Study Requirements: Attendance at Treatment Sessions | Topiramate/BBCET | Number of subjects completed through Visit 12 | 3 | participants | |
| Mean Drinks Per Day at Baseline vs. Visit 12 | Topiramate/BBCET | Mean drinks per day at baseline | 10.95 | Standard Deviation 13.85 | Drinks/day |
| Mean Drinks Per Day at Baseline vs. Visit 12 | Topiramate/BBCET | Mean drinks per day at Visit 12 | 0.68 | Standard Deviation 1.13 | Drinks/day |
| Mean Percent Days Abstinent Per Week at Baseline vs. Visit 12 | Topiramate/BBCET | Mean percent days abstinent per week at baseline | 20 | Standard Deviation 21.67 | Mean percent days abstinent per week |
| Mean Percent Days Abstinent Per Week at Baseline vs. Visit 12 | Topiramate/BBCET | Mean percent days abstinent per week at Visit 12 | 76.2 | Standard Deviation 7.14 | Mean percent days abstinent per week |
| Mean Binge Eating Episodes Per Week at Baseline vs. Visit 12 | Topiramate/BBCET | Mean weekly binge eating episodes at baseline | 3.7 | Standard Deviation 2.11 | Binge eating episodes/week |
| Mean Binge Eating Episodes Per Week at Baseline vs. Visit 12 | Topiramate/BBCET | Mean weekly binge eating episodes at Visit 12 | 1 | Standard Deviation 1.7 | Binge eating episodes/week |
| Compliance With Study Requirements: Topiramate Level | Topiramate/BBCET | 5 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Topiramate/BBCET | 5 | |
| Overall Study | COMPLETED | Topiramate/BBCET | 3 | |
| Overall Study | NOT COMPLETED | Topiramate/BBCET | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Topiramate/BBCET | ||
| Total, other adverse events | Topiramate/BBCET | 0 | 5 |
| Total, serious adverse events | Topiramate/BBCET | 0 | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00300742
GET https://conductscience.org/api/trials/v1/NCT00300742/registered